Vancomycin conjugated iron oxide nanoparticles for magnetic targeting and efficient capture of Gram-positive and Gram-negative bacteria

Rashid, Mehnaz; Rabbi, M. Ahasanur; Ara, Tabassum; Hossain, Mohammad Alamgir; Islam, Md. Shahidul; Elaı̈ssari, Abdelhamid; Ahmad, Hasan; Rahman, Md. Mahbubor

doi:10.1039/d1ra04390k

Cited by 19 publications

(15 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Magnetic nanoparticles (MNPs) have attracted significant attention for biomedical applications due to their tunable responses to static and electromagnetic fields and capability of generating heat under an alternating magnetic field. 1 For example, MNPs could serve as drug carriers to improve drug delivery to targeted sites for tissue repair 2 and antibacterial activity, 3 as a hyperthermia agent for cancer treatment, 4,5 or as a contrast agent to enhance magnetic resonance imaging for medical diagnostics. 6,7 MNPs have been synthesized with or without surface modifiers for different medical applications.…”

Section: Introductionmentioning

confidence: 99%

Angiogenic Hyaluronic Acid Hydrogels with Curcumin-Coated Magnetic Nanoparticles for Tissue Repair

Daya

Nguyen

et al. 2022

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Angiogenic magnetic hydrogels are attractive for tissue engineering applications because their integrated properties can improve angiogenesis while providing magnetic guidance and stimulation for tissue healing. In this study, we synthesized magnetic nanoparticles (MNPs) with curcumin as an angiogenic agent, referred to as CMNPs, via a one-pot coprecipitation method. We dispersed CMNPs in hyaluronic acid (HyA) to create angiogenic magnetic hydrogels. CMNPs showed a slightly reduced average diameter compared to that of MNPs and a curcumin content of 11.91%. CMNPs exhibited a sustained slow release of curcumin when immersed in a revised simulated body fluid (rSBF). Both CMNPs and MNPs showed a dose-dependent cytocompatibility when cultured with bone marrow-derived mesenchymal stem cells (BMSCs) using the direct exposure culture method in vitro. The average BMSC density increased when the concentrations of CMNPs or MNPs increased from 100 to 500 μg/mL, but the cell density decreased when the nanoparticle concentration reached 1000 μg/mL. CMNPs showed a weaker magnetic response than MNPs both in air and in water immediately after synthesis but retained the magnetism better than MNPs when embedded in the HyA hydrogel because of less oxidation. CMNPs were able to respond to magnetic guidance even when the porcine skin or muscle tissues were placed in between the nanoparticles and external magnet. The magnetic hydrogels of HyA_CMNP and HyA_MNP promoted the adhesion of BMSCs in a direct exposure culture. The HyA_CMNP group also showed the highest secretion of the vascular endothelial growth factor with the release of curcumin in vitro. Overall, our magnetic hydrogels integrated the desirable properties of cytocompatibility and angiogenesis with magnetic guidance, thus proving to be promising for improving tissue regeneration.

show abstract

Section: Introductionmentioning

confidence: 99%

Angiogenic Hyaluronic Acid Hydrogels with Curcumin-Coated Magnetic Nanoparticles for Tissue Repair

Daya

Nguyen

et al. 2022

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

show abstract

“…In this context, the use of technologies such as liposomes , and dendrimers has been investigated. In addition to these non-covalent drug delivery systems, progress has also been made in covalently loading vancomycin on dendrimers or metal nanoparticles (NPs). -− Cooper and colleagues conjugated an N- hydroxysuccinimide (NHS)-activated PEG-dibenzocyclooctyne (DBCO) to a human serum albumin monolayer bound to the surface of super-paramagnetic carboxylated 170 NPs . Subsequently, the NPs were loaded with vancomycin-PEG-N 3 at different densities, using a copper-free azide–alkyne cycloaddition reaction, yielding derivative 37 (Figure ).…”

Section: Recent Developments In Semisynthetic Glycopeptide Antibioticsmentioning

confidence: 99%

Recent Advances in the Development of Semisynthetic Glycopeptide Antibiotics: 2014–2022

2022

View full text Add to dashboard Cite

The accelerated appearance of drug-resistant bacteria poses an ever-growing threat to modern medicine’s capacity to fight infectious diseases. Gram-positive species such as methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus pneumoniae continue to contribute significantly to the global burden of antimicrobial resistance. For decades, the treatment of serious Gram-positive infections relied upon the glycopeptide family of antibiotics, typified by vancomycin, as a last line of defense. With the emergence of vancomycin resistance, the semisynthetic glycopeptides telavancin, dalbavancin, and oritavancin were developed. The clinical use of these compounds is somewhat limited due to toxicity concerns and their unusual pharmacokinetics, highlighting the importance of developing next-generation semisynthetic glycopeptides with enhanced antibacterial activities and improved safety profiles. This Review provides an updated overview of recent advancements made in the development of novel semisynthetic glycopeptides, spanning the period from 2014 to today. A wide range of approaches are covered, encompassing innovative strategies that have delivered semisynthetic glycopeptides with potent activities against Gram-positive bacteria, including drug-resistant strains. We also address recent efforts aimed at developing targeted therapies and advances made in extending the activity of the glycopeptides toward Gram-negative organisms.

show abstract

“…Rashid et al. 27 have reported the chemical conjugation of VM on MNPs via ligand exchange and carbodiimide reactions. Briefly, they first coated MNPs with oleic acid as stabilizer, and then oleic acid was replaced with the amine-ending dopamine to improve the water dispersion of MNPs.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…The resulting system showed targeted antibacterial activity against Gram-positive and Gram-negative bacterial strains with a lower VM dose than used in its free form. Rashid et al 27 have reported the chemical conjugation of VM on MNPs via ligand exchange and carbodiimide reactions. Briefly, they first coated MNPs with oleic acid as stabilizer, and then oleic acid was replaced with the amine-ending dopamine to improve the water dispersion of MNPs.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Silica-Coated Magnetic Nanoparticles for Vancomycin Conjugation

et al. 2022

View full text Add to dashboard Cite

Drug resistance is a global health challenge with thousands of deaths annually caused by bacterial multidrug resistance (MDR). Efforts to develop new antibacterial molecules do not meet the mounting needs imposed by the evolution of MDR. An alternative approach to overcome this challenge is developing targeted formulations that can enhance the therapeutic efficiency and limit side effects. In this aspect, vancomycin is a potent antibacterial agent that has inherent bacterial targeting properties by binding to the D-Ala-D-Ala moiety of the bacterial peptidoglycan. However, the use of vancomycin is associated with serious side effects that limit its clinical use. Herein, we report the development of vancomycin-conjugated magnetic nanoparticles using a simple conjugation method for targeted antibacterial activity. The nanoparticles were synthesized using a multistep process that starts by coating the nanoparticles with a silica layer, followed by binding an amide linker and then binding the vancomycin glycopeptide. The developed vancomycin-conjugated magnetic nanoparticles were observed to exhibit a spherical morphology and a particle size of 16.3 ± 2.6 nm, with a silica coating thickness of 5 nm and a total coating thickness of 8 nm. The vancomycin conjugation efficiency on the nanoparticles was measured spectrophotometrically to be 25.1%. Additionally, the developed formulation retained the magnetic activity of the nanoparticles, where it showed a saturation magnetization value of 51 emu/g, compared to 60 emu/g for bare magnetic nanoparticles. The in vitro cell biocompatibility demonstrated improved safety where vancomycin-conjugated nanoparticles showed IC 50 of 183.43 μg/mL, compared to a much lower value of 54.11 μg/mL for free vancomycin. While the antibacterial studies showed a comparable activity of the developed formulation, the minimum inhibitory concentration was 25 μg/mL, compared to 20 μg/mL for free vancomycin. Accordingly, the reported formulation can be used as a platform for the targeted and efficient delivery of other drugs.

show abstract

Vancomycin conjugated iron oxide nanoparticles for magnetic targeting and efficient capture of Gram-positive and Gram-negative bacteria

Abstract: (a) The separation of bacteria by vancomycin conjugated Fe3O4/DOPA/Van nanoparticles and (b) H-bonding interactions between the vancomycin molecule and the d-alanyl-d-alanine dipeptide of the bacterial surface.

Cited by 19 publications

References 52 publications

Angiogenic Hyaluronic Acid Hydrogels with Curcumin-Coated Magnetic Nanoparticles for Tissue Repair

Angiogenic Hyaluronic Acid Hydrogels with Curcumin-Coated Magnetic Nanoparticles for Tissue Repair

Recent Advances in the Development of Semisynthetic Glycopeptide Antibiotics: 2014–2022

Silica-Coated Magnetic Nanoparticles for Vancomycin Conjugation

Contact Info

Product

Resources

About